What is Humanin?
Humanin emerged from experiments examining neuronal cell survival. It is a research topic in mitochondrial and neurodegenerative biology, not an established dementia treatment.
Biological role or research focus
Cell-survival and neurodegeneration research.
Protection of experimental cells does not establish prevention or treatment of dementia.
Role reference: A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. ↗
- Class / identity
- Experimental cell-survival peptide
- Main research area
- Neuroprotection research
- Evidence featured
- Neuronal cell experiments
- Source check
- October 4, 2026
Quick answers
- Is Humanin FDA approved?
- No. No FDA-approved drug contains Humanin. Source ↗
- Is Humanin safe?
- Humanin is a natural mitochondrial peptide studied in cells and rodents. No human safety studies of humanin or its analogs have been published. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Humanin banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Original rescue-factor report (2001) | Neuronal cell experiments | Cultured neuronal cells exposed to familial Alzheimer-related genes or amyloid-beta. |
| Humanin and insulin action (2009) | Animal / laboratory study | Rodent metabolic experiments, including diabetic rats, with additional measurements of circulating humanin in humans and mice. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Neuronal cell experiments · 2001
Original rescue-factor report
A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta.
- Population / model
- Cultured neuronal cells exposed to familial Alzheimer-related genes or amyloid-beta.
- Study design
- Functional screening and experiments examining cell survival and peptide sequence.
- Main finding
- Humanin protected against several tested Alzheimer-related cell-death mechanisms, but did not protect against every other insult examined.
- Limits & context
- Selective cell protection is an early biological finding. The study did not test memory, dementia progression, or survival in patients.
Animal / laboratory study · 2009
Humanin and insulin action
What metabolic effects were observed in preclinical experiments?
- Population / model
- Rodent metabolic experiments, including diabetic rats, with additional measurements of circulating humanin in humans and mice.
- Study design
- Insulin-clamp experiments and signaling inhibition tested central humanin and peripheral derivatives; age-related levels were also examined.
- Main finding
- Humanin improved insulin sensitivity in the experiments. Blocking hypothalamic STAT-3 removed important effects. A potent analog reduced blood glucose in diabetic rats; measured humanin levels declined with age.
- How to read it
- Human biomarker observations and rodent intervention results provide different kinds of evidence.
- Limits & context
- No human treatment trial was conducted. Derivatives are not interchangeable with native humanin. These findings do not demonstrate human diabetes treatment, dementia prevention, lifespan extension, or clinical safety.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
3 registered studies name Humanin as an intervention; 1 is recruiting or under way, 0 have not started recruiting yet, 1 completed and 1 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Comparison of the Effects of General Anesthesia and Combined Spinal-Epidural Anesthesia on Ferroptosis, Humanin and MOTS-c Levels in Renal Transplantation NCT07678073 · University of Gaziantep | Recruiting | Not applicable | 2026-03-01 | 68 |
| Clinical Value of Plasma Humanin in Acute Kidney Injury NCT06105229 · Guangdong Provincial People's Hospital | Status unknown | 2022-08-01 | 60 | |
| Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac Operation NCT03431844 · University of Tartu | Completed | 2018-01-01 | 106 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Search additional PubMed records ↗Risks & interactions
Humanin is a natural mitochondrial peptide studied in cells and rodents. No human safety studies of humanin or its analogs have been published.
Human research has only measured natural humanin levels in blood. The effects of giving humanin or its analogs to people, including on blood sugar and insulin, are untested.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Humanin rescue factor in neuronal cells (2001) ↗ · Humanin as a central regulator of insulin action (2009) ↗
Safety evidence & remaining uncertainty
A cell-survival assay cannot characterize human adverse effects, interactions, or long-term exposure. Those remain separate questions from whether a cell survives an experimental insult.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
The paper provides a lead for therapeutic research. It does not establish prevention of dementia, improvement in memory, or a longevity use in humans.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
The original report described sequence-dependent protection against selected Alzheimer-related insults in cultured neurons. Protection was selective rather than universal across cell-death mechanisms.
Molecular structure
Questions worth asking
- Was the experiment in cells, animals, or people?
- Is the measured outcome the same one claimed in the video?
- Protection of experimental cells does not establish prevention or treatment of dementia.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Were people with Alzheimer disease treated in the cited study?
No. It was a cell-model investigation.
Does “humanin” mean the tested product is approved for humans?
No. A molecule’s name is not a regulatory or clinical-evidence designation.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Mitochondrial peptides: what MOTS-c, humanin and SS-31 (elamipretide) actually show in people
MOTS-c and humanin are made by mitochondria; elamipretide (SS-31) is a drug aimed at them. Mouse data and blood-level studies back the first two; only elamipretide has human trials and a narrow FDA approval.
Read the guide →
